GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Stilla Technologies Secures US Distribution Agreement with Avantor for Digital PCR Systems

NextEdge Admin

06 Jun 2024

1 min 34 sec

Stilla Technologies, a French developer of digital PCR systems, has announced a strategic distribution partnership with Avantor, headquartered in Radnor, Pennsylvania, for the US market. The financial details of the agreement were not disclosed. As per the deal, Avantor's life science specialists will distribute Stilla's dPCR products to researchers and clinicians across the US. Kerri McWeeny, Stilla's general manager for North America, expressed confidence in achieving their biopharma, applied testing, and academia objectives with Avantor's support.

Stilla, based in Paris with a presence in Boston, recently introduced the Nio+, a seven-color dPCR instrument, and secured a $26.5 million Series C financing round to bolster its marketing and sales efforts and expedite the commercialization of its system.

Avantor, known for its acquisitions of Puritan Products and VWR in 2017, operates an innovation center in Bridgewater, New Jersey, where it manufactures cell and gene therapy reagents. The company had previously formed a distribution agreement with Oxford Nanopore Technologies in 2021.